Prolight Diagnostics
0,16
SEK
-1,23 %
PRLD
Nordic SME
Medical Equipment & Services
Health Care
Vær den første som følger denne virksomhed
-1,23%
-1,84%
-33,05%
+12,68%
-46,84%
-52,38%
-86,53%
-90,86%
-62,79%
www.prolightdiagnostics.se/investor-relations
Prolight Diagnostics develops test systems in POCT (Point of care testing). The tests are used outside of hospital laboratories to enable rapid assessments of the health of patients. The company's POCT platform is under development with the intention of measuring various biomarkers simultaneously. An important component of the work is to reduce the time for test results, particularly important for patients with heart problems. The company was founded in 1999 and is based in Lund.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
Nordic SME
PRLD
Daglig lav / høj pris
0,152 / 0,167
SEK
Markedsværdi
112,33 mio. SEK
Aktieomsætning
150,59 t SEK
Volumen
946 t
Seneste videoer
Finanskalender
Årsrapport
21.02.2025
Delårsrapport
14.05.2025
Delårsrapport
28.08.2025
Større aktionærerKilde: Millistream Market Data AB
| Ejer | Kapital | Stemmer |
|---|---|---|
| Julie Richards | 5,3 % | 5,3 % |
| Paul Brendan Monagan | 5,3 % | 5,3 % |
| Steven Andrew Ross | 5,3 % | 5,3 % |
| Aileen McGettrick | 5,3 % | 5,3 % |
| Avanza Pension | 3,9 % | 3,9 % |
| Nordic Underwriting APS | 2,8 % | 2,8 % |
| The Bank of New York Mellon, W9 | 1,9 % | 1,9 % |
| Cardeon AB | 1,6 % | 1,6 % |
| Tuvedalen Limited | 0,8 % | 0,8 % |
| Handelsbanken Livförsäkringsaktiebolag | 0,8 % | 0,8 % |
ViserAlle indholdstyper
Emergers: Equity Research | PROLIGHT: Commercial prototype marks an important milestone towards upcoming studies
Prolight achieves significant milestone with arrival of first Psyros™ commercial prototype instruments
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools